Arbutus Biopharma Corporation (ABUS)
NASDAQ: ABUS · Real-Time Price · USD
4.460
+0.050 (1.13%)
Jul 21, 2026, 9:57 AM EDT - Market open
Arbutus Biopharma Revenue
Arbutus Biopharma had revenue of $179.13M in the quarter ending March 31, 2026, with 10,054.54% growth. This brings the company's revenue in the last twelve months to $191.45M, up 2,889.93% year-over-year. In the year 2025, Arbutus Biopharma had annual revenue of $14.08M with 128.21% growth.
Revenue (ttm)
$191.45M
Revenue Growth
+2,889.93%
P/S Ratio
4.55
Revenue / Employee
$10,076,053
Employees
19
Market Cap
881.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 14.08M | 7.91M | 128.21% |
| Dec 31, 2024 | 6.17M | -11.97M | -65.98% |
| Dec 31, 2023 | 18.14M | -20.88M | -53.51% |
| Dec 31, 2022 | 39.02M | 28.03M | 255.11% |
| Dec 31, 2021 | 10.99M | 4.07M | 58.92% |
| Dec 31, 2020 | 6.91M | 903.00K | 15.02% |
| Dec 31, 2019 | 6.01M | 66.00K | 1.11% |
| Dec 31, 2018 | 5.95M | -4.76M | -44.44% |
| Dec 31, 2017 | 10.70M | 9.21M | 617.64% |
| Dec 31, 2016 | 1.49M | -21.79M | -93.59% |
| Dec 31, 2015 | 23.28M | 8.32M | 55.66% |
| Dec 31, 2014 | 14.95M | -512.00K | -3.31% |
| Dec 31, 2013 | 15.47M | 1.36M | 9.64% |
| Dec 31, 2012 | 14.11M | -2.19M | -13.44% |
| Dec 31, 2011 | 16.30M | -5.13M | -23.95% |
| Dec 31, 2010 | 21.43M | 7.66M | 55.67% |
| Dec 31, 2009 | 13.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 369.49M |
| Phathom Pharmaceuticals | 204.89M |
| Geron | 196.12M |
| Theravance Biopharma | 109.78M |
| DBV Technologies | 5.04M |
| Odyssey Therapeutics | 1.06M |
ABUS News
- 5 days ago - Arbutus Biopharma expects to return $230M in capital to shareholders - TheFly
- 5 days ago - Arbutus initiates patent infringement actions against Pfizer, BioNTech - TheFly
- 5 days ago - Arbutus Biopharma receives $178M settlement agreement from Moderna - TheFly
- 5 days ago - Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - GlobeNewsWire
- 2 months ago - Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arbutus Biopharma Quarterly report: Q1 2026 - Filings
- 2 months ago - Arbutus Biopharma Earnings release: Q1 2026 - Filings
- 3 months ago - Arbutus Biopharma granted Fast Track designation for imdusiran - TheFly